Kornimate/medical-research-clean huggingface dataset:
engineered dendritic cell vaccines for multiple myeloma

Conditions: Multiple Myeloma or Plasmacytoma

Summary: the purpose of this study is to determine the feasibility, safety, and efficacy of dendritic cell (dc) vaccines in the treatment of multiple myeloma (mm) or plasmacytoma based on immune-modified dc vaccines (dcvac). this approach is aimed to achieve prolonged maintenance of remission in multiple myeloma or plasmacytoma patients.

multiple myeloma (mm) is a plasma cell malignancy, characterized by the aberrant occupation of bone marrow with malignant plasma cells, and the destruction of bones together with the production of abnormal immunoglobulins. the clinical symptoms and signs can be manifested through various mechanisms. at present, the therapeutic drugs for mm include glucocorticoid, cytotoxic drugs, immunosuppressants, protease inhibitors, monoclonal antibodies and cell therapies including hematopoietic stem cell transplantation (hsct). among them, immunotherapy has been proven to be a revolutionary treatment with great potential of producing long term cure. in the past decades, adoptively transferred t cells modified with chimeric antigen receptors (cars) have demonstrated high effectiveness, and the car-t therapy has changed the treatment paradigm for many hematological malignancies. currently, several antibody-based therapies and a few bcma-based car-t cell therapies have been approved for mm treatment. however, in many mm patients, the disease may still relapse after extensive immunotherapies including auto- and allo-hsct. we have previously reported a dc-based immune activation strategy against mm in a preclinical study. this study proposes to apply the individual patients' mm tumor antigen-based dcs as vaccines (dcvac) to booster anti-myeloma immunity, in order to prevent disease relapse. the mm patients who have achieved very good partial or complete remission will be treated with multiple dcvacs to achieve a prolonged remission without disease recurrence. this trial protocol will inject dcvacs to mm or plasmacytoma patients who have been treated with a combination of anti-cancer regimens, including car-t cell therapy, and who have achieved partial or complete disease remission. the dcvacs are patient's own dcs which are immune modified to present target antigens and to activate anti-cancer immunity. the aim of this study is to evaluate the feasibility, safety, and efficacy of the innovative mm patient-based dc vaccines.

Eligibility criteria:
inclusion criteria: * male and female subjects with multiple myeloma or plasmacytoma * very good partial or complete remission (cr) after prior combination therapies. * expected survival \> 12 weeks * adequate venous access for blood withdrawal or apheresis, and no other contraindications for blood withdrawal * voluntary informed consent is given with willingness to continue follow up exclusion criteria: * pregnant or lactating women * uncontrolled active infection * hiv or active hepatitis b or hepatitis c infection * concurrent use of systemic steroids; the use of inhaled steroids is not exclusionary

Keywords: mm car t dc vaccine
complete versus partial open incisional hernia repair (compac-trial)

Conditions: Incisional Hernia

Summary: to compare the complete repair of the abdominal wall at the level of the former incision with only a partial repair at the level of the hernia in patients with an incisional hernia after median laparotomy in a prospective randomized trial.


Eligibility criteria:
inclusion criteria: * written informed consent from the patient or his/her legal representative * incisional hernia requiring elective surgical repair exclusion criteria: * no written informed consent * emergency surgery (incarcerated hernia) * all incisional or parastomal hernias not originating at the midline * all recurrent hernias * all patients with mesh placed intra-abdominally during surgery have to be withdrawn
national study on the interest of eeg-fmri in the presurgical evaluation of partial epilepsies drug

Conditions: Epilepsy Intractable; Focal Epilepsy

Summary: the main goal of this study is to evaluate the additional value of eeg-fmri method in the presurgical evaluation of focal intractable epilepsy. to consider a patient for surgery, the main difficulty is to define accurately the epileptogenic zone. this definition is complex and is often supported by several types of exploration (mri, fdg pet, neuropsychological testing, video-eeg...). in this study we will evaluate the adding value of the simultaneous recording of eeg and fmri in the epileptogenic zone definition.


Eligibility criteria:
inclusion criteria: * \> 8 years old * intractable focal epilepsy * presurgical evaluation or "phase 1" planified * with focal eeg activity : more than 3 eeg interictal epileptic events per hour * patient and/or legal representant given their written consent for their participation in the study exclusion criteria: * mri contraindication * pregnancy * uncomfortable prolonged lying position * frequent primary or secondary generalised seizure with tonic clonic movements (\>2 per week) * previous epilepsy surgery * important mental retardation

Keywords: eeg-fmri brain imaging presurgical evaluation epilepsy surgery
efficacy of educational intervention as supporting element in the treatment of functional constipation in children

Conditions: Constipation - Functional

Summary: the purpose of this study is to determine whether educational intervention (recommendation of adequate fluid intake) is effective as an element supporting the treatment of functional constipation in children.

constipation is a common condition in children which affects around 10% of the paediatric population. in 95 % cases it is a functional disorder of the digestive tract, without any organic cause. recommendations of lifestyle modifications accompanying pharmacological treatment of constipation are very popular among healthcare providers, although there is limited data concerning non-pharmacological treatment methods of this condition. adequate for age fluid intake is now recommended for patients with constipation. further research is needed to form stronger recommendations in the future. the purpose of this study is to determine whether educational intervention (recommendation of adequate fluid intake) is effective as an element supporting the treatment of functional constipation in children.

Eligibility criteria:
inclusion criteria: children with functional constipation diagnosed based on rome iv criteria exclusion criteria: 1. children with organic causes of constipation; eg, anorectal malformations, or hirschsprung's disease 2. children who fulfil the criteria of irritable bowel syndrome 3. significant, unstabilised chronic health conditions requiring major drug adjustment during the last 3 months. 4. unintentional weight loss greater than or equal to 5% of their body weight within the last 3 months 5. recurrent or unexplained fevers 6. history of abdominal surgery involving the luminal gastrointestinal tract, except appendectomy, or hernia repairs 7. concomitant use of drugs that are known to affect gastrointestinal motility 8. established diagnoses of autism spectrum disorders 9. mental retardation 10. children who are exclusively breastfed 11. non-retentive faecal incontinence

Keywords: fluid intake functional constipation children peg macrogol educational intervention
the use of botox in advanced parkinson's patients experiencing pain

Conditions: Parkinson's Disease

Summary: most parkinsonism related pain can be assigned to one or more of five categories: musculoskeletal pain, neuritic or radicular pain, dystonia associated pain, primary or central pain, and akathitic discomfort. in pd pain tends to affect the side of the body that was initially, or more severe affected by the motor symptoms. botulinum toxins are an effective treatment modality for a growing number of neurological conditions. they have been studied for a variety of conditions associated with pd including dystonia, jaw tremor, apraxia of eyelid opening, camptocormia, dyskinesias, freezing of gait, sialhorrea, overactive bladder and constipation. there are no studies for the use of botulinum toxin for pain in pd. the investigators will perform a double-blind, randomized cross-over study evaluating the efficacy and safety of an individual pattern of btxa injections targeted at painful muscles vs. placebo injection.

the investigators will perform a double-blind, randomized cross-over study evaluating the efficacy and safety of an individual pattern of btxa injections targeted at painful muscles vs. placebo injection. primary outcome will be a measure of global pain as perceived by the participants. to assess this endpoint the investigators will use:1. change in pain on a numeric rating scale (nrs) by telephone between btxa and placebo injections at 4 week post injection and 2.change in visual analogue scale (edmonton symptom assessment system: numerical scale) at study visits. secondary outcomes will be the percentage of responders, physician rated clinical global impression (cgi), unified parkinson disease rating scale (mds-updrs) on medication, quality of life by parkinson disease questionnaire (pdq-39) and adverse events as assessed at each study visit.

Eligibility criteria:
inclusion criteria: * subjects with advanced pd (hoehn and yahr 3-5) and painful limbs not responding to antiparkinsonian agents sufficiently. * btxa treatment naã-ve patients or not received any within last 12 months (including other indications). * stable pd and pain medications for at least 30 days * competence to self-report pain severity in a visual analogue scale (vas) exclusion criteria: * subjects with a primary cause of pain unrelated with pd and associated with another medical condition e.g. severe arthritis * subjects that because of the severity or refractory pain are under an unfixed analgesic schedule * subjects unable to self- report pain severity in a vas * subjects undergoing acute infections or other acute intercurrences. * any contraindication to receiving btxa injections: 1. subjects who are hypersensitive to any btxa or to any ingredient in the formulation or component of the container (clostridium botulinum toxin type a neurotoxin complex 900 kd, human serum albumin and sodium chloride). 2. the presence of infection at the proposed injection site(s).
effect of acupuncture on chronic nonspecific neck pain and insomnia

Conditions: Neck Pain Chronic; Insomnia Chronic

Summary: the study aims to assess the efficacy and safety of acupuncture among patients with chronic nonspecific neck pain and insomnia, compared with sham acupuncture.


Eligibility criteria:
inclusion criteria: 1. aged 18 to 75 years old; 2. meet the diagnostic criteria for both chronic nonspecific neck pain and chronic insomnia; 3. the patient's average neck pain intensity score on the numeric rating scale (nrs) over the past 3 days is ≥3; 4. the patient's insomnia severity index (isi) score is ≥10; 5. the patient is willing to participate in the study and has signed the informed consent form. exclusion criteria: 1. specific neck pain with a clear etiology, including trauma, tumor, connective tissue disease, rheumatic disease, metabolic and endocrine disorders, neuropathy, spinal cord disease, fracture, or vertebral misalignment; 2. positive spurling test, neck flexion test, upper limb traction test, or foraminal distraction test. neck pain accompanied by radiating pain in the upper limbs or radicular compression symptoms, or acute exacerbation of neck pain; 3. neck pain accompanied by sensory disturbances or other neurological symptoms, or ankylosis of the facet joints; 4. previous history of cervical spine surgery; 5. previous history of head and neck trauma, such as whiplash injury; 6. insomnia caused by medications (e.g., caffeine, corticosteroids), withdrawal reactions, or other underlying conditions (e.g., hyperthyroidism, severe anxiety/depressive disorders); 7. long-term use of analgesics, muscle relaxants, or hormones, or presence of other pain more severe than neck pain; 8. other sleep disorders, such as sleep apnea syndrome, or shift workers; 9. presence of psychiatric disorders (e.g., depression), cognitive impairment, or language disorders; 10. patients with drug dependency; 11. received acupuncture treatment within the past month; 12. severe cardiovascular, hepatic, renal, hematologic, autoimmune diseases, infectious diseases, poor general nutritional status, malignancy, or patients in the terminal stage of severe illness; 13. pregnant or planning to become pregnant within the next year, breastfeeding, or postpartum ≤12 months.
validation of functional imaging as predictive tool for outcome of mandibular replacement appliance therapy in obstructive sleep apnea hypopnea syndrome patients

Conditions: Obstructive Sleep Apnea Syndrome

Summary: in this open prospective study 40 patients who received mandibular replacement appliance (mra) therapy as treatment of obstructive sleep apnea hypopnea syndrome (osahs) will be included. the patient's sleep will be registered during 2 periods of 2 days: one while the patient does not wear the mra and, +/- 1 week later, one while the patient wears the mra. furthermore, 2 low dose ct scans (one with and one without the mra device in the mouth) will be taken. these data must allow the investigators to validate the use of functional imaging (segmentation and computational fluid dynamics) as a predictor of the outcome of the mra therapy in osahs patients.


Eligibility criteria:
inclusion criteria: 1. patients with documented osahs based on the following criteria: ahi \>= 5 complaints of extreme daytime sleepiness with no other explanation and/or 2 or more of the following symptoms: * choking or gasping during sleep * recurrent awakenings from sleep * un-refreshing sleep * daytime fatigue * impaired concentration 2. patients who received mra as treatment for osahs 3. ahi \>= 5 on at least 1 of the screening nights (patient does not wear mra device) 4. male or female patients aged ≥ 18 years 5. patients with a co-operative attitude 6. written informed consent obtained exclusion criteria: 1. pregnant or lactating females or females at risk of pregnancy 2. patients with an uncontrolled disease or any condition that might, in the judgement of the investigator, place the patient at undue risk or potentially compromise the results or interpretation of the study. 3. cancer or any other chronic disease with poor prognosis and/or affecting patient status 4. history of alcohol or drug abuse in the last 2 years 5. patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study 6. patients who participate in another clinical study whose investigational plan is judged to interfere or affect any of the measures of this study

Keywords: osas ahi mra cfd
predictive multimodal mri factors in subacute cerebral artery occlusiontreated by thrombectomy (pimisutt)

Conditions: Middle Cerebral Artery Acute Ischemic Stroke

Summary: our study aims to measure metabolic and functional parameters of the infarcted territory by multimodal cerebral mri in patients diagnosed with unilateral proximal occlusion of the middle cerebral artery and treated by thrombectomy in order to correlate those parameters to clinical outcome (evaluated by modified rankin score) at 3 months. we aim to find early radiologic predictive factors for favorable clinical outcome in this population of patients.

the treatment of acute ischemic stroke in the setting of intracranial large artery occlusion and especially middle cerebral artery occlusion (mcao) with intravenous tissue plasminogen activator (iv-tpa) is associated with low rates of recanalization and high rates of neurological morbidity and functional dependence. in the last few years, endovascular intervention (mechanical thrombectomy) has proven its safety and its efficacy on clinical outcome in patients diagnosed with mcao and is now commonly recommended. however, in this population of patients treated by thrombectomy, very few predictive factors, except for the post-procedural recanalization score (tici), do exist to foresee the variability of clinical outcome. tissue viability of the infarcted territory can be approached by the measure of metabolic and morphological parameters (na+, h+, phosphore, diffusion imaging) which can be non-invasively done by multimodal mri, as suggest by recently published studies. our study plans to measure these parameters between 12 and 24 hours after acute ischemic stroke in patients with mcao treated by thrombectomy in order to correlate those parameters to clinical outcome at 3 months (modifier rankin score).

Eligibility criteria:
inclusion criteria: * patients aged ≥ 18 years old * hospitalized at the poitiers university hospital * acute middle cerebral artery occlusion diagnosed by ct-scan or mri * nihss score ≥ 6 at admission * to be treated by thrombectomy with or without fibrinolysis * written information delivered to the patient or his relatives concerning the study and its benefit and risk exclusion criteria: * patients or relatives whom a loyal information about the study cannot be given * patient with cognitive impairments before mri. * patients who cannot undergo mri because of contraindications * patients too deteriorated to tolerate one hour long exam

Keywords: ischemic stroke acute middle cerebral artery occlusion multimodal mri thrombectomy
window of opportunity study of ipi-549 in patients with locally advanced hpv+ and hpv- head and neck squamous cell carcinoma

Conditions: Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer; Head and Neck Carcinoma; Head and Neck Cancer Stage IV; Head and Neck Cancer Stage III; HPV-Related Carcinoma; HPV-Related Malignancy; HPV-Related Squamous Cell Carcinoma

Summary: the purpose of this study is to investigate how effective the study drug ipi-549 is against types of cancers. ipi-549 is considered experimental because it is not approved by the us food and drug administration (fda) for the treatment of cancer. patients will be treated with 2 weeks of ipi-549, a specific pi3kγ inhibitor. tumor tissue for research purposes through core biopsies will be obtained prior to initiation of ipi-549 and at surgery.

this is a phase 2 window of opportunity trial in patients with locally advanced head and neck cancer. a key objective is to provide the first proof that macrophage phenotype switching can be accomplished in humans and lay the groundwork for future trials of this novel approach to immune therapy. patients who are candidates for surgical resection will be enrolled and treated with 2 weeks of ipi-549, a specific pi3kγ inhibitor. tumor tissue for research purposes through core biopsies will be obtained prior to initiation of ipi-549 and at surgery. the study team hypothesizes that mrna signatures of immune response will be increased in ipi-549-treated patients. for the efficacy endpoints, recistv1.1 will be used.

Eligibility criteria:
inclusion criteria: * have locally advanced that is amenable to surgical resection * must be able to swallow tablets * must be able to undergo a core tumor biopsy. * must have adequate organ function. exclusion criteria: * diagnosis of cutaneous squamous cell carcinoma (scc) or epstein-barr virus (ebv) related nasopharynx cancer. * planned major surgery within 4 weeks prior to initiation of study drug * patients treated with chemotherapy, biologic therapy, or other investigational agent within \< 28 days of starting study drug * history of infection with human immunodeficiency virus (hiv), hepatitis b, or hepatitis c virus (hcv) * on going treatment with chronic immunosuppressants (e.g., cyclosporine) or systemic steroids * prior surgery or gastrointestinal dysfunction that may affect drug absorption (e.g. gastric bypass surgery, gastrectomy) * female subjects who are pregnant or breastfeeding * concurrent active malignancy other than nonmelanoma skin cancer, carcinoma in situ of the cervix, or prostate intraepithelial neoplasia

Keywords: hpv positive hpv negative hpv- hpv+ pi3k-γ microenvironment immunotherapy tumor resection pi3k cancer carcinoma malignancy head neck throat esophageal nasopharyngeal nasopharynx
patient engagement initiative

Conditions: Critical Illness

Summary: a no-cost intervention may improve adherence with a recommendation for higher-quality, lower-cost care for patients with critical illness endorsed by a collaborative of critical care societies. the investigators propose prompting consideration of functional outcomes. this trial will help establish the impact of the intervention on practice patterns including proxy engagement and elements of shared decision-making.


Eligibility criteria:
inclusion criteria: * licensed physicians * at least 4 weeks of clinical work in an i.c.u. in the u.s.a. during the past 12 months exclusion criteria: * \<25 years old * non-english speaking * primarily practicing medicine outside the u.s.a.
effects of kinesio taping techniques in copd patients

Conditions: Chronic Obstructive Pulmonary Disease

Summary: study will investigate effects of two different kinesio taping techniques on pulmonary parameters of patients with copd.

chronic obstructive pulmonary disease (copd) is an irreversible, progressive, treatable airway disease which causes dyspnea, wheezing, coughing and increased secretions in airways. thoracic and respiratory mechanics are impaired, respiratory muscle strength and functional exercise capacity is decreased in patients with copd. as a result dyspnea, limitation in activities of daily living, postural impairments, muscle length-strength relationship changes and increased mechanical loads on respiratory muscles occur. in literature it has been demonstrated that kinesio taping have therapeutic effects on respiratory functions and functional exercise capacity in patients with chronic neurological diseases who has additional respiratory impairments. although there are several studies in literature investigating the effects of facilitation and inhibition taping techniques applied on respiratory muscles in patients with copd, effects of thoracic and postural mechanical correction techniques as an alternative treatment modality in patients with copd have not been investigated yet. in present study, effects of thoracic mechanical correction and facilitation taping techniques in patients with copd will be investigated, and data will be collected for effects of thoracic mechanical correction taping on pulmonary parameters in patients with copd.

Eligibility criteria:
inclusion criteria: * male and female copd patients aged between 40-80 years * diagnosed with copd stage i-ii-iii-iv according to gold 2019 criterias * able to speak, understand and read turkish language * volunteering to participate in study exclusion criteria: * unstable or acutely exacerbated patients with copd * alterations in medical treatment in last 6 months * having comorbidities that affect directly cardiopulmonary system, uncontrolled arterial hypertension, severe congestive heart failure, coronary arterial disease, heart valve disease * orthopaedic, neurological, psychiatric disease, peripheral/central nervous system diseases, mental retardation, antidepressants usage, metabolic impairments, malignancy * unable to cooperate for measurement and treatment techniques used in study * irritation, infection, allergic reaction, scarred burn or open wound around application area * enrolled in a comprehensive pulmonary rehabilitation program before study * application of kinesio tape to any body region in the past * history of an open heart surgery or other thoracic surgeries

Keywords: chronic obstructive pulmonary disease mechanical correction facilitation thoracic taping kinesio taping respiratory muscle strength pulmonary functions functional exercise capacity